Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 6, 2026
Reporting Period: Second Quarter ended June 30, 2026
This filing announces the financial results for the second quarter of 2026. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the referenced press release (Exhibit 99.1), which is not included in the input content.
Material Changes
No material changes versus the prior comparable period are described in the provided text. The document serves only to notify the SEC of the announcement of results.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release for management commentary but does not include the text of that commentary.
Legal Disclaimer: The information in this Form 8-K and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of Sections 11 and 12(a)(2) of the Securities Act. It shall not be deemed incorporated by reference in any other filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net income, and EPS figures.
- Verify full-year 2026 guidance and outlook provided in the press release.
- Check for any updates on clinical trial progress or regulatory approvals mentioned in the full press release.
- Confirm the company's liquidity position and debt levels as detailed in the referenced financial statements.